Adagio Therapeutics Inc

-0.28 (-9.49%)
Earnings Announcements

Adagio Therapeutics Posts Q1 Net Loss Per Share Of $0.93

Published: 05/13/2022 11:51 GMT
Adagio Therapeutics Inc (ADGI) - Adagio Therapeutics Reports First Quarter 2022 Financial Results.
$532.2 Million in Total Cash at Quarter End; Strong Balance Sheet Expected to Support Operations Into Second Half of 2024.
Basic and Diluted Net Loss per Share Was $0.93 for the First Quarter of 2022.
Q1 Earnings per Share View $-0.82 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.53

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.41

More details on our Analysts Page.